Phase 2 Trial into Potential Oral Alzheimer’s Treatment Safe to Continue, Independent Board Says
A Phase 2 clinical trial testing Annovis Bio’s oral therapy ANV401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review by the study’s independent Data Safety Monitoring Board (DSMB).